Asthma afflicts more than 25 million Americans, a number that has been increasing since the early 1980s in all age, sex, and racial groups. Uncontrolled asthma not only affects quality of life but disproportionately increases healthcare utilization and morbidity.
Current guideline-directed treatment focuses on a stepwise approach consisting of increasing doses of medications, primarily inhaled corticosteroids. Despite adherence to such therapies, many patients with moderate to severe asthma still experience symptoms and exacerbations.
In this panel ReCAP, Drs David Rosenstreich and Joan Reibman discuss the important distinction between severe and hard-to-control asthma, and explore the effective use of newer biologic therapies in this patient population. With three classes of biologics each acting against specific targets, the physicians consider factors for choosing appropriate therapies for individual patients.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Severe Asthma - Medscape - Mar 24, 2020.
Comments